Treating defective dura with synthetic artificial dura substitute
View Patent ↗Disclosed are an artificial dura mater and manufacturing method thereof. The artificial dura mater includes electrospun layers prepared by electrostatic spinning, at least one of which is a hydrophobic electrospun layer. Further, above the hydrophobic electrospun layer, there can be at least one hydrophilic electrospun layer. A transition layer can be further included between the hydrophobic and the hydrophilic electrospun layers. Additionally, cytokines and/or medicines can be affixed to either or both of the hydrophobic and the hydrophilic electrospun layers, by way of bio-printing. The disclosed artificial dura mater shows good biocompatibility, enhances dural tissue regeneration, achieves excellent repairing effects, prevents adhesion, allows complete absorption, has good mechanical properties, ensures low infection rates, and can be loaded with therapeutic agents.
1. A method of treating a subject having a defective dura mater, comprising implanting an artificial dura mater proximate to said defective dura mater in the brain of said subject, wherein said artificial dura mater consists essentially of synthetic materials and comprises at least a hydrophobic and biodegradable electrospun layer comprising 30% polylactic acid (PLA), and wherein said hydrophobic electrospun layer comprises fibers with a diameter of 50-1000 nM and pores with a size of less than 3 μM.
2. The method according to claim 1 , wherein said artificial dura mater further comprises at least a hydrophilic electrospun layer disposed on said hydrophobic electrospun layer.
3. The method according to claim 2 , wherein said hydrophilic electrospun layer is prepared, by a method comprising electrospinning, with one or more hydrophilic polymers selected from the group consisting of chondroitine sulfate, heparin, agar, glucan, algin, modified cellulose, alginate, starch, cellulose, gelatin, fibrinogen, silk protein, elastin-mimicry peptide polymer, collagen, chitosan, modified chitosan, hydrophilic polyurethane, polyethylene glycol, polymethylmethacrylate, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx), polyvinyl alcohol, polylactide and mixtures thereof.
4. The method according to claim 2 , wherein said artificial dura mater further comprises a transition layer disposed between the hydrophobic and hydrophilic electrospun layers, wherein said transition layer has hydrophilicity that gradually increases from the side proximate to said hydrophobic electrospun layer to the side proximate to said hydrophilic electrospun layer.
5. The method according to claim 1 or 2 , wherein said artificial dura mater further comprises a cytokine and/or a medicine that is adhered to said hydrophobic electrospun layer and/or said hydrophilic electrospun layer.
6. The method according to claim 5 , wherein said cytokine is selected from the group consisting of interleukin, colony stimulating factor, tumor necrosis factor, platelet derived growth factor, basic fibroblast growth factor and combinations thereof.
7. The method according to claim 5 , wherein said medicine is one or more selected from the group consisting of an antibiotic, a hemostat, an anti-adhesion agent and an anti-tumor drug.
8. The method according to claim 5 , wherein said cytokine and/or medicine is enclosed in a hydrogel.
9. The method according to claim 8 , wherein said hydrogel comprises one or more selected from the group consisting of polysaccharide polymer, polypeptide polymer and synthetic hydrophilic high molecular polymer.
10. A method of treating a subject having a defective dura mater, comprising implanting an artificial dura mater proximate to said defective dura mater in the brain of said subject, wherein said artificial dura mater consists essentially of synthetic materials and comprises at least a hydrophobic and biodegradable electrospun layer comprising 50% polylactic acid, and wherein said hydrophobic electrospun layer comprises fibers with a diameter of 50-1000 nM and pores with a size of less than 3 μM.
11. The method of claim 10 , wherein said biodegradable electrospun layer comprises 50% polylactic acid and 50% ε-caprolactone.